IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

abstract：:Cancer immunotherapy aims at eliciting an immune response directed against tumor antigens to help fight off residual tumor cells and, thereby, improve the survival and quality of life of cancer patients. Different immunotherapeutic approaches share the use of dendritic cells (DCs) to present tumor-associated antigens ...

journal_title：Expert review of anticancer therapy

authors： Tyagi RK,Mangal S,Garg N,Sharma PK

更新日期：2009-01-01 00:00:00

abstract：INTRODUCTION:In the last decade tyrosine kinase inhibitors (TKIs) have been employed for a wide range of hematological and solid tumors and today they represent a valid therapeutic option for different neoplasms. Among them, both sorafenib and lenvatinib were approved for the treatment of radioactive iodine (RAI) refra...

journal_title：Expert review of anticancer therapy

authors： Felicetti F,Nervo A,Piovesan A,Berardelli R,Marchisio F,Gallo M,Arvat E

更新日期：2017-12-01 00:00:00

abstract：:Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved. Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbocicli...

journal_title：Expert review of anticancer therapy

authors： Onesti CE,Jerusalem G

更新日期：2020-12-13 00:00:00

abstract：:Ca(2+) influx at critical points in the cell cycle is required for proliferation. This requirement is so ubiquitous that its occurrence is often treated as background noise. Yet without it, cells stop dividing, suggesting an obvious and potentially effective way to treat cancer. To control proliferation by controlling...

journal_title：Expert review of anticancer therapy

authors： Gray LS,Schiff D,Macdonald TL

更新日期：2013-05-01 00:00:00

abstract：:Approximately 25% of breast cancer patients without lymph node metastases develop systemic relapse. A growing body of data supports the notion that hematogenous dissemination of breast cancer cells occurs independently of lymphatic spread of disease; however, current clinical practice does not involve routine analysis...

journal_title：Expert review of anticancer therapy

authors： Lang JE,Hall CS,Singh B,Lucci A

更新日期：2007-10-01 00:00:00

abstract：:This article reviews the current status of robotic-assisted radical prostatectomy (RARP) with outcome analysis. The published English literature (PubMed) database was searched extensively for major publications and large series on RARP. The search was carried out over the preceding 3-year period. Selected series were ...

journal_title：Expert review of anticancer therapy

authors： Singh I,Hemal AK

更新日期：2010-05-01 00:00:00

abstract：INTRODUCTION:The treatment landscape of metastatic prostate cancer has changed dramatically over the past five years. As new discoveries are made and further novel therapies become available, there is a heightened urgency to develop biomarkers that can guide prognoses and predict therapy responses. Circulating tumor ce...

journal_title：Expert review of anticancer therapy

authors： Parimi S,Ko JJ

更新日期：2017-10-01 00:00:00

abstract：INTRODUCTION:Outcomes in metastatic colorectal cancer are improving, with better understanding and use of targeted therapies. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This article reviews the current ...

journal_title：Expert review of anticancer therapy

authors： Price TJ,Tang M,Gibbs P,Haller DG,Peeters M,Arnold D,Segelov E,Roy A,Tebbutt N,Pavlakis N,Karapetis C,Burge M,Shapiro J

更新日期：2018-10-01 00:00:00

abstract：:The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and melanoma progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signaling can inhibit multiple cellular processes involved in melanoma progression and me...

journal_title：Expert review of anticancer therapy

authors： De Giorgi V,Grazzini M,Gandini S,Benemei S,Asbury CD,Marchionni N,Geppetti P

更新日期：2012-11-01 00:00:00

abstract：:In this report, we first describe the history of transsphenoidal surgery. We further elaborate on three fundamental surgical anatomy principles of transsphenoidal surgery for pituitary adenomas. First, the pituitary gland and, therefore, pituitary adenomas are extra-arachnoid structures, therefore the operation should...

journal_title：Expert review of anticancer therapy

authors： Ciric IS,Zhao J

更新日期：2006-09-01 00:00:00

abstract：INTRODUCTION:Angiogenesis is a complex process regulated by several pro- and anti-angiogenic factors, thus the loss of its fine equilibrium plays a key role in colorectal cancer (CRC) development and progression. Therapeutic agents targeting VEGF/VEGFR signaling, the main regulator of this process, proved to be effecti...

journal_title：Expert review of anticancer therapy

authors： Battaglin F,Puccini A,Intini R,Schirripa M,Ferro A,Bergamo F,Lonardi S,Zagonel V,Lenz HJ,Loupakis F

更新日期：2018-03-01 00:00:00

abstract：:Introduction: It has long been recognized that tumors are composed of a mosaic of cells and numerous methods have been developed to detect tumor heterogeneity, including in situ hybridization, multi-regional sampling, cytological assays, and whole genome and single cell sequencing. Using these methods, heterogeneity h...

journal_title：Expert review of anticancer therapy

authors： Turnquist C,Watson RA,Protheroe A,Verrill C,Sivakumar S

更新日期：2019-10-01 00:00:00

abstract：:Sarcomas are a rare family of heterogeneous tumors of mesenchymal origin characterized by their bad prognosis. In addition, limited active therapeutic options are available. The cytotoxic drug gemcitabine and the inhibition of the mTOR pathway have demonstrated modest activity in sarcomas as monotherapy. However, prec...

journal_title：Expert review of anticancer therapy

authors： Martin-Liberal J,Tirado OM,García del Muro X

更新日期：2015-03-01 00:00:00

abstract：:Introduction: The microbiota is recognized for its impact on both human health and disease. The human microbiota is made up of trillions of cells, including bacteria, viruses, and fungi. The largest population of microbes reside in the gut, prompting research for better understanding of the impact of gastrointestinal ...

journal_title：Expert review of anticancer therapy

authors： Garajová I,Balsano R,Wang H,Leonardi F,Giovannetti E,Deng D,Peters GJ

更新日期：2020-12-08 00:00:00

abstract：:Subungual melanoma (SUM) is infrequent in the general population, accounting for 0.7-3.5% of all cutaneous melanomas. SUM absolute incidence is similar among different racial groups; however, the relative proportion among overall cutaneous melanoma cases within each population varies in relation to the frequency of su...

journal_title：Expert review of anticancer therapy

authors： De Giorgi V,Saggini A,Grazzini M,Gori A,Rossari S,Scarfì F,Verdelli A,Chimenti S,Lotti T,Massi D

更新日期：2011-05-01 00:00:00

abstract：INTRODUCTION:Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of breast or ovarian carcinoma. STIC is a pa...

journal_title：Expert review of anticancer therapy

authors： Weinberger V,Bednarikova M,Cibula D,Zikan M

更新日期：2016-12-01 00:00:00

abstract：INTRODUCTION:In breast cancer, estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: tempora...

journal_title：Expert review of anticancer therapy

authors： Martínez-Pérez C,Turnbull AK,Dixon JM

更新日期：2019-02-01 00:00:00

abstract：:Introduction: Radiotherapy is an important therapeutic strategy in the management of non-small cell lung cancer (NSCLC). In recent decades, technological implementations and the introduction of image guided radiotherapy (IGRT) have significantly increased the accuracy and tolerability of radiation therapy.Area covered...

journal_title：Expert review of anticancer therapy

authors： Giaj-Levra N,Borghetti P,Bruni A,Ciammella P,Cuccia F,Fozza A,Franceschini D,Scotti V,Vagge S,Alongi F

更新日期：2020-05-01 00:00:00

abstract：:The incidence of colorectal cancers is rising worldwide and pulmonary metastases were seen in approximately 10-15% of all patients. Surgical metastasectomy is a widely accepted procedure in selected patients and is considered as the only curative option in patients with secondary pulmonary malignancy. But surgical res...

journal_title：Expert review of anticancer therapy

authors： Limmer S,Unger L

更新日期：2011-10-01 00:00:00

abstract：:Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years there have been significant advances in the treatment of CRPC. In addition to cytotoxic chemotherapy, treating physicians and their patients now have the option of several new agents that tar...

journal_title：Expert review of anticancer therapy

authors： Shapiro D,Tareen B

更新日期：2012-07-01 00:00:00

abstract：:Hematopoietic stem cell transplantation is an effective treatment for patients with relapsed or refractory Hodgkin lymphoma. Treatment outcome is better among patients who demonstrate sensitivity to salvage chemotherapy. Approximately half of the patients undergoing autologous stem cell transplantation will be cured a...

journal_title：Expert review of anticancer therapy

authors： Murphy F,Sirohi B,Cunningham D

更新日期：2007-03-01 00:00:00

abstract：:Bone metastases are common among patients with stage IV genitourinary cancers. Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event. These events are associated with increased medical expenses and decreased quality of life. Current guidelines recomme...

journal_title：Expert review of anticancer therapy

authors： Mulders PF,Abrahamsson PA,Bukowski RM

更新日期：2010-11-01 00:00:00

abstract：:Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of these patients and is considered the standard of care. Nevertheless, 40-50% of patients have impaired renal function that p...

journal_title：Expert review of anticancer therapy

authors： Bournakis E,Dimopoulos MA,Bamias A

更新日期：2011-06-01 00:00:00

abstract：:B cells play an important role in the pathogenesis of certain lymphomas and leukemias, as well as many autoimmune diseases. Antagonistic B-cell antibodies are thus gaining an increasing role in the management of these diseases. The first antibody target in this regard was CD20, with the development and introduction of...

journal_title：Expert review of anticancer therapy

authors： Goldenberg DM

更新日期：2006-10-01 00:00:00

abstract：:As diagnostic and therapeutic options increase, strategies for the treatment of non-small-cell lung cancer (NSCLC) are becoming more tailored for specific patient subpopulations and individual patients. The introduction of therapy targeted against the EGF receptor (EGFR) pathway has provided new treatment options for ...

journal_title：Expert review of anticancer therapy

authors： Batus M,Fidler MJ,Bonomi PD

更新日期：2010-10-01 00:00:00

abstract：:Results of clinical trials over the past 15 years demonstrate that the taxanes are among the most effective new class of cytotoxic drugs to treat breast cancer and other solid tumors. Moreover, the efficacy of the taxanes added further credence to the relevance of the microtubule as a tumor target. In spite of the sig...

journal_title：Expert review of anticancer therapy

authors： Higa GM,Abraham J

更新日期：2008-05-01 00:00:00

abstract：:In breast cancer, RANK ligand (RANKL) appears to play an important role in the process of chemotaxis between circulating tumor cells and the bone microenvironment, which enables RANK-expressing breast cancer cells to migrate into the bone. Mounting clinical evidence has further demonstrated that the anti-RANKL monoclo...

journal_title：Expert review of anticancer therapy

authors： Azim H,Azim HA Jr

更新日期：2013-02-01 00:00:00

abstract：INTRODUCTION:PI3K inhibitors are an important new therapeutic option for the treatment of relapsed and refractory B-cell lymphoid malignancies. Idelalisib is a PI3Kδ inhibitor that has been approved for the treatment of lymphoma and chronic lymphocytic leukemia in the relapsed/refractory setting, and several other PI3K...

journal_title：Expert review of anticancer therapy

authors： Greenwell IB,Flowers CR,Blum KA,Cohen JB

更新日期：2017-03-01 00:00:00

abstract：INTRODUCTION:Immunotherapy has emerged as a major class in the therapeutic arsenal of multiple myeloma. Cell-based immunotherapy (CAR T-cells) and monoclonal antibody-based immunotherapy (naked monoclonal antibodies, antibody-drug conjugates, and bispecific T-cell engagers) are the two cornerstones of this novel approa...

journal_title：Expert review of anticancer therapy

authors： Jullien M,Touzeau C,Moreau P

更新日期：2020-10-26 00:00:00

abstract：:Bladder cancer is a significant cause of morbidity and mortality. Promising results with organ preservation strategies using multimodality treatment over the last decade offers an option for bladder preservation in a significant proportion of patients who currently undergo cystectomy. The primary goal of the bladder-s...

journal_title：Expert review of anticancer therapy

authors： Hussain SA,James ND

更新日期：2002-12-01 00:00:00